Department of Medicinal Chemistry, Institute of Molecular Biology and Genetics, the NAS of Ukraine, 150 Zabolotnogo St, 03143, Kyiv, Ukraine.
Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University of Mainz, Staudinger Weg 5, 55128, Mainz, Germany.
J Antibiot (Tokyo). 2022 Jun;75(6):321-332. doi: 10.1038/s41429-022-00524-8. Epub 2022 Apr 19.
Staphylococcus aureus is one of the most dangerous pathogens commonly associated with high levels of morbidity and mortality. Sortase A is considered as a promising molecular target for the development of antistaphylococcal agents. Using hybrid virtual screening approach and FRET analysis, we have identified five compounds able to decrease the activity of sortase A by more than 50% at the concentration of 200 µM. The most promising compound was 2-(2-amino-3-chloro-benzoylamino)-benzoic acid which was able to inhibit S. aureus sortase A at the IC value of 59.7 µM. This compound was selective toward sortase A compared to other four cysteine proteases - cathepsin L, cathepsin B, rhodesain, and the SARS-CoV2 main protease. Microscale thermophoresis experiments confirmed that this compound bound sortase A with K value of 189 µM. Antibacterial and antibiofilm assays also confirmed high specificity of the hit compound against two standard and three wild-type, S. aureus hospital infection isolates. The effect of the compound on biofilms produced by two S. aureus ATCC strains was also observed suggesting that the compound reduced biofilm formation by changing the biofilm structure and thickness.
金黄色葡萄球菌是一种最危险的病原体之一,常与高发病率和死亡率有关。天冬酰胺酰基内肽酶 A 被认为是开发抗葡萄球菌药物的有前途的分子靶标。我们使用混合虚拟筛选方法和 FRET 分析,鉴定出 5 种能够在 200μM 浓度下使天冬酰胺酰基内肽酶 A 活性降低 50%以上的化合物。最有前途的化合物是 2-(2-氨基-3-氯苯甲酰氨基)苯甲酸,其能够在 IC 值为 59.7μM 时抑制金黄色葡萄球菌天冬酰胺酰基内肽酶 A。与其他四种半胱氨酸蛋白酶——组织蛋白酶 L、组织蛋白酶 B、rhodesain 和 SARS-CoV2 主蛋白酶相比,该化合物对天冬酰胺酰基内肽酶 A 具有选择性。微量热泳动实验证实该化合物与天冬酰胺酰基内肽酶 A 的 K 值为 189μM。抗菌和抗生物膜试验也证实了该化合物对两种标准和三种野生型金黄色葡萄球菌医院感染分离株的高特异性。还观察到该化合物对两种金黄色葡萄球菌 ATCC 菌株产生的生物膜的影响,表明该化合物通过改变生物膜结构和厚度来减少生物膜的形成。